MPLNET.com » News » MPLN expands oncology offering with Next Generation Sequencing based mutation panels for evaluation Client Login | Email | Phone: 1.800.932.2943

MPLN expands oncology offering with Next Generation Sequencing based mutation panels for evaluation


Posted on May 18, 2017 by J Seabrook

Myeloproliferative neoplasms (MPNs) are characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute leukemia.  Clinical data and practice guidelines have evolved at a rapid pace for this heterogeneous group of disorders, and the role of mutation analysis for primary diagnosis and guidance of therapy has expanded significantly.  To date, conventional approaches to mutation profiling have involved complex, sequentially cascaded testing algorithms that are resource intensive and often inefficient. With the advent of next generation sequencing (NGS), multiplex targeted gene panels now provide a practical solution for comprehensive mutation analysis in routine clinical practice.  MPLN NGS panel content is based on NCCN and updated WHO practice guidelines.

Read more about Myeloproliferative Neoplasms

Commenting is turned off for this post.

Commenting is not available in this channel entry.